Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2024 | Neutral → Overweight | Cantor Fitzgerald | |
| 11/19/2024 | $2.00 → $7.00 | Market Perform → Outperform | Leerink Partners |
| 11/19/2024 | $8.00 | Neutral → Buy | BTIG Research |
| 11/19/2024 | $2.00 → $7.00 | Hold → Buy | Jefferies |
| 11/18/2024 | $3.00 → $13.00 | Neutral → Overweight | Piper Sandler |
| 1/22/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/13/2023 | Outperform → Mkt Perform | William Blair | |
| 10/3/2023 | $22.00 | Outperform | Evercore ISI |
- Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl
– First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an important milestone for Aclaris with the dosing of our first patient in the Phase 2a trial of ATI-2138 for moderate to severe atopic dermatitis," said Dr. Neal Walker, Interim President & CEO and Chair of
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "With study activities underway for our ATI-2138 Phase 2a trial in moderate to severe atopic dermatitis and the strengthening of our balance sheet through the completion of our royalty purchase agreement wi
CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations. "We are very excited that we continue further strengthening our team through the addition of experienced industry veterans with successful track records," said Neal Walker, Chief Executive Officer of Aclaris. "Bob brings to Aclaris considerable experience leading investor relations programs across a number of various therapeutic sectors." Mr. Doody has nearly 20 years of biotechnology i
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered single digit sales royaltyAclaris Therapeutics will be responsible for development and commercialization of BSI-045B, a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R worldwide (excluding Greater China)NEWARK, Del. and NANJING, China, Nov. 18, 2024 /PRNewswire/ -- Biosion, Inc. (Biosion), a global R&D stage biotechnology company, today announce
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) (the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million. The private placement is expected to close on or about November 19, 2024, subject to the satisfaction of customary closing conditions. The private placement was led by Vivo Capital, with partic
- Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl
Cantor Fitzgerald upgraded Aclaris Therapeutics from Neutral to Overweight
Leerink Partners upgraded Aclaris Therapeutics from Market Perform to Outperform and set a new price target of $7.00 from $2.00 previously
BTIG Research upgraded Aclaris Therapeutics from Neutral to Buy and set a new price target of $8.00
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. BranchOut Food The Trade: BranchOut Food Inc. (NASDAQ:BOF) Director Byron Riche Jones bought a total of 41,755 shares at an average price of $0.99. To acquire these shares, it cost around $41,337. What's Happening: On June 26, Branchout Foo
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Neutral.
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)